Can kinomics and proteomics bridge the gap between pediatric cancers and newly designed kinase inhibitors?

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Kinase inhibitors have transformed chronic myeloid leukemia treatment by targeting BCR-ABL.
• Multiple kinase inhibitors have been developed, yet their clinical use in pediatric malignancies is limited.
• Intracellular protein signaling networks regulate cancer hallmarks, suggesting a target for improved kinase inhibitor implementation.

Purpose of the Study:

• To provide an overview of current kinase inhibitor implementation strategies in cancer medicine.
• To discuss the limitations hindering the use of kinase inhibitors in pediatric cancers.
• To propose a future personalized medicine approach to bridge the gap in pediatric cancer treatment.

Main Methods:

• Literature review of current kinase inhibitor strategies.
• Analysis of reasons for limited use in pediatric oncology.
• Proposal of a personalized medicine framework integrating kinomics, proteomics, and drug screening.

Main Results:

• Chronic myeloid leukemia transformed from fatal to manageable due to kinase inhibitors.
• Significant challenges exist in applying current kinase inhibitor strategies to pediatric cancers.
• A personalized medicine approach offers a promising strategy for pediatric cancer treatment.

Conclusions:

• Targeting intracellular protein signaling networks is crucial for advancing kinase inhibitor therapy.
• A personalized medicine strategy combining kinomics, proteomics, and drug screening can improve kinase inhibitor use in pediatric cancers.
• Bridging the gap requires a multi-omics and drug screening approach for tailored pediatric cancer therapies.